Kamada

Kamada Ltd. is a biopharmaceutical company, which focuses on specialty plasma-derived therapeutic. It operates through the Proprietary Products and Distribution segments. The Proprietary Products segment covers the development, manufacture, and sale of plasma-derived protein therapeutics products. The Distribution segment covers the drug products in Israel, which are manufactured by third parties. The company was founded by David Tsur and Ralf Hahn on December 13, 1990 and is headquartered in Rehovot, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Kamada reports robust earnings, eyes global expansion and clinical milestones

Kamada's strong financial performance, strategic acquisitions, and global expansion efforts position the company for continued growth and market success.
While facing challenges in maintaining growth momentum and operational efficiency, Kamada's focus on innovation and market expansion presents significant opportunities for future development.
Investors should monitor Kamada's progress in clinical trials, product diversification, and international market penetration to assess the company's long-term growth potential and market positioning.

Kamada secures $60M investment, targets 35% revenue growth in 2023

Kamada's Q1 2023 performance showed revenue and EBITDA growth, supported by strategic investments and regulatory approvals. While facing rising expenses and financial challenges, the company aims for significant revenue growth in 2023 through market expansion and trial acceleration.

Kamada (KMDA) reports strong Q2 earnings and secures $60M investment

Kamada (KMDA) delivered robust financial results in Q2 2023, with significant revenue growth and positive EBITDA performance.
The company's strategic investments, diverse product pipeline, and regulatory progress underscore its potential for future growth and market expansion.
Stable cash position, operational efficiency, and ongoing clinical advancements position Kamada favorably in the biopharmaceutical industry.
Overall, Kamada's Q2 performance and future outlook reflect a promising trajectory for sustained growth and value creation for shareholders.

Kamada reports robust Q3 earnings, eyes growth through clinical trials

Kamada's Q3 2023 earnings call highlighted strong financial performance, debt-free status, and strategic initiatives for future growth. The company's focus on product development, clinical trials, and board expertise positions it well for continued success and profitability.

Kamada reports robust 2023 earnings, eyes growth through strategic initiatives

Kamada's strong financial performance in 2023 and positive outlook for 2024 underscore the company's growth trajectory and market positioning.
While facing challenges such as rising operating expenses, Kamada's focus on innovation, market expansion, and strategic partnerships presents opportunities for sustained growth.
Maintaining a robust balance sheet and advancing key clinical trials reflect Kamada's commitment to financial stability, product development, and long-term value creation.

Kamada doubles profitability in Q1 2024, eyes revenue growth

Kamada delivered robust financial performance in Q1 2024, with doubled profitability and revenue growth driven by key products. The company's strategic initiatives, including product launches and clinical trial progress, position it well for future success. While facing cost pressures, Kamada's strong cash position and focus on innovation present opportunities for sustained growth.

Kamada excels in Q2, eyes global expansion and clinical milestones

Kamada's strong financial performance in Q2 2024 and the first half of the year, coupled with reaffirmed full-year guidance, reflect a positive growth trajectory and financial stability.
The company's strategic focus on organic growth, M&A activities, and clinical trials positions it well to capitalize on market opportunities and drive future revenue expansion.
While challenges such as dividend policy, regulatory timelines, and market competition exist, Kamada's proactive approach to business development and global partnerships underscores its commitment to sustained growth and innovation.

Kamada reports strong Q3 earnings, eyes growth in clinical trials

Kamada's Q3 2024 earnings call highlighted robust financial performance, increased guidance, and strategic initiatives driving growth and market expansion.
With a strong balance sheet, ongoing clinical trials, and expansion plans, Kamada is well-positioned to capitalize on market opportunities and sustain growth momentum.
While challenges such as market competition and integration risks exist, Kamada's proactive approach to innovation, partnerships, and operational efficiency bodes well for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

REHOVOT, Israel and HOBOKEN, N.J., July 06, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, announced today that it has secured an $11.4 million agreement to supply VARIZIG® to an undisclosed international organization, operating principally in Latin America. The supply of the product is expected to occur from the fourth quarter of 2022 through the first half of 2023.

Kamada Announces $11.4 Million International VARIZIG® Procurement Agreement

REHOVOT, Israel, and HOBOKEN, N.J., June 15, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, announced today the promotions of Shavit Beladev to Vice President responsible for the Company's Plasma Operations, and Boris Gorelik to Vice President of Business Development and Strategic Programs, both reporting to Kamada's CEO, Amir London. Ms. Beladev will be responsible for the operations and expansion of Kamada Plasma, the Company's wholly owned U.S.-based plasma collection subsidiary. Mr. Gorelik will be responsible for the advancement of existing and new business development opportunities, as well as managing Kamada's existing strategic partner relationships.

Kamada Strengthens Senior Leadership Team; Furthering Commitment as a Fully Integrated Global Leader in the Specialty Plasma-Derived Therapeutics Market

Kamada Ltd. (NASDAQ:KMDA ) Q1 2022 Earnings Conference Call May 17, 2022 8:30 AM ET Company Participants Bob Yedid - LifeSci Advisors Amir London - Chief Executive Officer Chaime Orlev - Chief Financial Officer Conference Call Participants Operator Greetings.

Kamada Ltd. (KMDA) CEO Amir London on Q1 2022 Results - Earnings Call Transcript

Kamada (KMDA) delivered earnings and revenue surprises of -233.33% and 13.37%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Kamada (KMDA) Reports Q1 Loss, Lags Revenue Estimates

REHOVOT, Israel, May 17, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today announced financial results for the three months ended March 31, 2022.

Kamada Reports First Quarter 2022 Financial Results; Reiterates Revenue and Profitability Guidance with Significant Growth Expected in 2022

REHOVOT, Israel, May 11, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today announced that it will release financial results for the first quarter ended March 31, 2022, prior to the open of the U.S. financial markets on Tuesday, May 17, 2022.

Kamada to Announce First Quarter Ended March 31, 2022 Financial Results and Host Conference Call on May 17, 2022

Kamada Ltd.'s (KMDA) CEO Amir London on Q4 2021 Results - Earnings Call Transcript

REHOVOT, Israel, March 15, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today issued the Letter to Shareholders from Amir London, Chief Executive Officer.

Kamada Issues 2022 CEO Letter to Shareholders

REHOVOT, Israel, March 15, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today announced financial results for the 12 and three months ended December 31, 2021.

Kamada Reports Fiscal Year and Fourth Quarter 2021 Financial Results; Provides Revenue and Profitability Guidance with Significant Growth Expected in 2022

Kamada Ltd. (KMDA) CEO Amir London on Q3 2021 Results - Earnings Call Transcript

Kamada Ltd (NASDAQ: KMDA) has acquired four FDA-approved plasma-derived hyperimmune commercial products from Saol Therapeutics. Kamada will pay Saol a $95 million upfront payment and an additional $50 million in sales milestones during 2022-2034.

Kamada Stock Jumps After Acquisition Of Four Plasma-Derived Products

Kamada (KMDA) delivered earnings and revenue surprises of -166.67% and 8.60%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Kamada (KMDA) Reports Q3 Loss, Lags Revenue Estimates

Kamada (NASDAQ:KMDA) reported its Q3 earnings results on Monday, November 22, 2021 at 08:00 AM. Here's what investors need to know about the announcement.

Kamada: Q3 Earnings Insights

REHOVOT, Israel, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced that it has acquired a portfolio of four U.S. Food and Drug Administration (FDA)-approved plasma-derived hyperimmune commercial products from Saol Therapeutics (“Saol”), a commercial specialty pharmaceutical company focused on addressing the medical needs of underserved or unserved patient populations. The combined annual global revenue of the acquired portfolio in 2021 is expected to be between $40 million to $45 million, with approximately 75% and 20% of sales generated in the U.S. and Canada, respectively. The acquired products' expected 2021 gross margins are between 50%-55%.

Kamada Announces Strategic Transformational Transaction Positioning the Company as a Global Leader in the Plasma-Derived Hyperimmune Market Through the Acquisition of a Portfolio of Four FDA-Approved Commercial Products

REHOVOT, Israel, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced financial results for the three and nine months ended September 30, 2021.

Kamada Reports Third Quarter and First Nine Months of 2021 Financial Results, and Strategic Transformational Acquisition of a Portfolio of Four FDA-Approved Plasma-Derived Hyperimmune Commercial Products

Kamada (NASDAQ:KMDA) is set to give its latest quarterly earnings report on Monday, 2021-11-22. Here's what investors need to know before the announcement.

Kamada's Earnings: A Preview

Kamada Limited (KMDA) CEO Amir London on Q2 2021 Results - Earnings Call Transcript

Kamada (KMDA) delivered earnings and revenue surprises of -60.00% and -5.63%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Kamada (KMDA) Q2 Earnings and Revenues Miss Estimates

REHOVOT, Israel, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced financial results for the three and six months ended June 30, 2021.

Kamada Reports Second Quarter and First Half 2021 Financial Results, Recent Achievements and Corporate Development Activities

Kamada (KMDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Kamada (KMDA) to Report a Decline in Earnings: What to Look Out for

FORT LEE, N.J. and REHOVOT, Israel, June 2, 2021 /PRNewswire/ -- Kedrion Biopharma and Kamada Ltd.

Kedrion and Kamada Announce FDA Approval of KEDRAB® Label Update, Confirming Safety and Effectiveness in Children

Kamada's (KMDA) CEO Amir London on Q1 2021 Results - Earnings Call Transcript

Kamada (KMDA) delivered earnings and revenue surprises of 20.00% and -5.86%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Kamada (KMDA) Q1 Earnings Top Estimates

REHOVOT, Israel, May 12, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced financial results for the three months ended March 31, 2021.

Kamada Reports First Quarter 2021 Financial Results, Recent Achievements and Corporate Development Activities

On Wednesday, May 12, Kamada (NASDAQ:KMDA) will report its last quarter's earnings. Here is Benzinga's preview of the company's release.

News for Kamada Stock (KMDA)